Best Life Sciences Companies in Pays de la Loire, France
The 47 best Life Sciences companies in Pays de la Loire, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: AbolerIS Pharma.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 62% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Pays de la Loire
| # | Company | Last round | Disclosed funding | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AI4R Developer of a real-time autoradiography system for cancer diagnostics | — | — | 9 | Jerome Donnard Founder | — | — | 12 patents Radiation detection and characterization of solid samples containing alpha/beta emitters | — |
| 2 | Algenics Recombinant therapeutics suing microbial technology | — | — | — | Morgan Cabigliera Founder & CEO | — | — | 21 patents Engineered microalgae platforms for recombinant therapeutic protein and antibody production | — |
| 3 | Atlanbio Bioanalytical services | — | — | — | Jacques Girault Founder | — | — | — | — |
| 4 | Atonco Developer of radiopharmaceuticals to treat cancer | — | — | — | Sylvain Fanier Managing Director | — | — | — | — |
| 5 | Bio Logbook Provider of decision support software for doctors and research scientists | — | — | — | Ronan Boutin CEO | — | — | — | — |
| 6 | Biosensor Develops bioelectronic sensors for medicine applications | — | — | — | Pierre Vangeluwe Founder | — | — | — | — |
| 7 | Biowest Reagents and kits for cell culture research | — | — | 9 | Holli Riebel CEO & President | Cart FunctionalityWooCommerceWordPress+39 | Top 5M | — | — |
| 8 | BluePro An oral appliance to prevent snoring and obstructive sleep apnea | — | — | 3 | Erwan Floch Founder & CEO | WordPress Block EditorCart FunctionalityWooCommerce+23 | Top 50M | — | — |
Top 12 Life Sciences companies in Pays de la Loire
#1
Public · Nantes, Pays de la Loire · founded 1986 · 61 employees$13.5Mraised▾
Developer of immunotherapies for immuno-oncology and autoimmune diseases. The lead candidate of the company is Tedopi vaccine for lung, ovarian and pancreatic cancer. Other products include the CoVepiT vaccine for covid-19, OSE-172, CLEC-1, and bispecific fusion protein platform for multiple cancer, OSE -127 for ulcerative colitis, Sjogren's syndrome, FR104 for autoimmune disease, transplantation, and OSE-230 for inflammation.
- Apr 2024Grant (prize money)$9.1M
- Jun 2023Grant (prize money)$1.5M
- Jun 2017Post IPO$2.9M
#2
Series A · Nantes, Pays de la Loire · founded 2019 · 12 employees$32Mraised▾
Developer of therapeutic solutions for treating immunological disorders. The company's proprietary platform aims to develop an anti-CD45RC monoclonal antibody to deplete effector T cells, preserve regulatory and memory T cells. It induces immune tolerance and preserves immune responses in inflammatory, autoimmune, and degenerative diseases. It has also developed an IL-34 cytokine that helps to induce tolerogenic macrophages.
- Sep 2023Series A$29.1M
- Nov 2020Seed$2.9M
#3
Series A · Nantes, Pays de la Loire · founded 2014 · 25 employees$3.3Mraised▾
Xenothera is a French biotech developing immunosuppressants for transplantation and other indications. It has a platform for the creation of hyperimmune polyclonal sera. Xenothera works on the therapeutic domains on Immunology, Oncology, and Infectious Diseases. They currently have a lead product for kidney transplant recipients (Rabbit-generated anti-thymocyte globulins (ATGs), which target human T cells), and have raised EUR 2M funds in Jun 2016 to take it to clinical trials.
- Jul 2022Grant (prize money)$51.1K
- Aug 2020Grant (prize money)$2.5M
- Mar 2017Grant (prize money)$53.7K
- Dec 2016Grant (prize money)$53.3K
#4
Seed · Nantes, Pays de la Loire · founded 2019 · 17 employees$2.8Mraised▾
Provider of hardware to help the motor handicap. The company offers medical devices, including prostheses and assistive robotics, based on technologies of 3D printing, advanced material, and open-source hardware.
- Feb 2023Seed$2.2M
- 2019Seed$572.2K
#5
Acquired · Saint Barthelemy d Anjou, Pays de la Loire · founded 2010 · 59 employees$15.9Mraised▾
Manufacturer of a hemodialysis monitoring device. The product S3 monitors and performs SeCoHD therapy via a succession of back-filtration and ultrafiltration phases, throughout the dialysis session. The product can also be used at home and clinics.
- Nov 2016Series A$15.9M
#6
Late Stage · Nantes, Pays de la Loire · founded 1999 · 160 employees$13.4Mraised▾
Designer and manufacturer of orthopedic prostheses and implants based in Briennon, France. The company specializes in offering a range of products including artificial joints for hip, knee, shoulder and wrists, enabling hospitals and clinics to install and implant on patients.
- Jan 2017PE$13.4M
#7
Series A · Nantes, Pays de la Loire · founded 2013 · 8 employees$8.8Mraised▾
InFlectis BioScience is developing small molecule drugs that specifically target the cellular defenses against misfolded proteins to treat neurodegenerative, age-related and other protein misfolding diseases. The company's pipeline is focused on neurodegenerative and orphan diseases with lead programs in Charcot-Marie-Tooth and Retinitis Pigmentosa. Its lead candidate IFB-088 modulate the Ubiquitin/Proteasome System (UPR) through a new and validated protein-protein interaction (phosphatase PP1/PPP1R15A) and developing IFB-008 for the treatment of orphan neurodegenerative diseases, such as Charcot-Marie-Tooth and Retinal diseases in the first instance.
- Jun 2016Series A$6.7M
- Jan 2015Seed$2.1M
#8
Series A · Nantes, Pays de la Loire · founded 2015 · 25 employees$3.6Mraised▾
i-Sep develops advanced cell salvage solutions. Intraoperative blood salvage, also known as autologous blood transfusion or cell salvage, is a medical procedure involving recovering blood lost during surgery and re-infusing it into the patient. It is a form of autotransfusion. These are used frequently in cardiothoracic and vascular surgery, in which blood usage has traditionally been high. With a greater effort to avoid adverse events due totransfusion there has also been an emphasis on blood conservation.
- Sep 2019Series A$2.7M
- Nov 2015Seed$880.1K
#9
Acqui-Hired · Nantes, Pays de la Loire · founded 2008 · 1 employees$7.9Mraised▾
ATLAB Pharma is developing radio immunotherapy for cancer treatment. Radio immunotherapy is a tumor-specific delivery system using monoclonal antibodies conjugated to radioisotopes (radio-antibodies) to target radiation to cancer cells. Its lead drug candidate, ATL101, has been shown to have a favorable safety profile and anti-tumor activity in Phase I and Phase II clinical trials in patients with castrate-resistant prostate cancer. ATL101 combines the humanized J591 monoclonal antibody targeting prostate-specific membrane antigen (PSMA) and the Lutetium-177 radioisotope.
- Jun 2009Grant (prize money)$7.9M
- PE—
#10
Seed · Laval, Pays de la Loire · founded 2007 · 21 employees$417.8Kraised▾
The company GenoUrob specializes in design, production and marketing of medical devices and associated software for the evaluation of the state and performance of the ligamentous structures of the knee. Their devices include Automated Dynamic Laximetry, LDA devices for evaluation of knee-ligaments by automated performance of tests to measure laxity. Their product range is available in more than 18 countries.
- Nov 2019Grant (prize money)$55K
- Jul 2019Grant (prize money)$56.4K
- May 2015Seed—
- 2011Seed$417.8K
#11
Funding Raised · Nantes, Pays de la Loire · founded 2005$1.6Mraised▾
In-Cell-Art specializes in the preclinical and pharmaceutical development of proprietary nanocarriers (Nanotaxi) for different therapeutic applications (vaccines, cancers, etc.). The CSO & Founder is Bruno Pitard and Jean-Marie Lehn (Nobel Laureate- 1987) is a founder and in the Scientific Advisory Board. The company was co-financed by the US Defense Advanced Research Projects Agency (DARPA) for a four-year project (budget USD33.1 M) with Sanofi-Pasteur and CureVac on RNArmorvax. RNArmorvax seeks to create a universal vaccine platform based on mRNA. EMER-IT (IMMUNOTHERAPY against EMERGING diseases) is a public-private project of USD 20 M for developing immunotherapy for pandemic viruses such as SARS, Ebola and Avian Flu H5N1.
- Feb 2016Grant (prize money)—
- Mar 2012Grant (prize money)$1.6M
#12
Seed · Thouare sur Loire, Pays de la Loire · founded 2012 · 5 employees$1.3Mraised▾
Aqualeg is developing a solution for protecting the prostheses utilizing softshell technology. The coating is resistant to acetone, acids, alcohol, and fire. It can be used in water as well. It also prevents bacterial growth.
- Feb 2013Seed$659.4K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in France
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,220 France-affiliated papers.
- Centre National de la Recherche Scientifique280
- Inserm169
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement144
- Ministry of Agriculture118
- AgroParisTech36
- Gene3→26
- Genome2→14
- Antibody1→10
- Cell culture1→10
- Mutant1→10
- Gene2→30
- Agriculture1→20
- Selection (genetic algorithm)2→18
- Resistance (ecology)2→16
- Population1→12
- Agriculture2→13
- Antibiotic resistance3→12
- Population1→9
- Public health1→8
- Context (archaeology)2→9
Where biotechnology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in France
France biotechnology patent filing is cooling — 34,222 filings from 8,000 assignees (2016–2025), led by Centre NAT RECH Scient, INST NAT Sante RECH MED, Sanofi; annual filings 3501→2745.
- Centre NAT RECH Scient10040
- INST NAT Sante RECH MED8292
- Sanofi3990
- Pasteur Institut3416
- Agronomique INST NAT RECH1331
- Cellectis1320
- PF Medicament1203
- Commissariat Energie Atomique1151
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.